Gene Therapy: Panacea or Placebo? I. Strategies and Limitations of Gene Therapy

Archivum Immunologiae et Therapiae Experimentalis

Volumn 45, Issue 5-6, 1997, Pages 367-374

  Górecki, Dariusz C ^a   Macdermot, Kay D ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Direct DNA injection; Gene targeting; Gene therapy; Immunogenicity; Liposomes; Viral vectors

Indexed keywords

ANIMAL; GENE THERAPY; HUMAN; METHODOLOGY; REVIEW;

ANIMALS; GENE THERAPY; HUMANS;

EID: 0031309313     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. AMALFITANO A., BEGY C. R. and CHAMBERLAIN J. S. (1996). Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc. Natl. Acad. Sci. USA, 93, 3352-3356.
2. ANDERSEN J. K., GARBER D. A., MEANEY C. A. and BREAKEFIELD X. O. (1992): Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Hum. Gene Ther., 3, 487-499.
3. BITTNER R. E., SHORNY S., STREUBEL B., HUBNER C., VOIT T. and KRESS W. (1995): Serum antibodies to the deleted dystrophin sequence after cardiac transplantation in a patient with Becker's muscular dystrophy. N. Engl. J. Med., 333, 732-733.
4. - SCID: initial trial results after 4 years. Science, 270, 475-480.
5. BLOMER U., NALDINI L., VERMA I. M., TRONO D. and GAGE F. H. (1996): Applications of gene therapy to the CNS. Hum. Mol. Genet., 5, 1397-1404.
6. - immunodeficient patients. Science, 270, 470-475.
7. COLE-STRAUSS A., YOON K., XIANG Y., BYRNE B. C., RICE M. C., GRYN J., HOLLOMAN W. K. and KMIEC E. B. (1996): Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science, 273, 1386-1389.
8. DAVIES N. P. (1995): How long should we wait for a big MAC? Gene Ther., 2, 299-300.
9. DOWTY M. E. and WOLFF J. A. (1994): Possible mechanisms of DNA uptake in skeletal muscle. In WOLFF J. A. (ed.): Gene therapeutics. Methods and applications of direct gene transfer. Birkhauser, Boston, 82-98.
10. EFSTATHIOU S. and MINSON A. C. (1995): Herpes virus-based vectors. In LEVER A. M. L. and GOODFELLOW P. (eds.): Gene therapy. Br. Med. Bull., 51, 45-55.
11. FERRARI F. K., SAMULSKI T., SHENK T. and SAMULSKI R. J. (1996): Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol., 70, 3227-3234.
12. FLOTTE T. R. and CARTER B. J. (1995): Adeno-associated virus vectors for gene therapy. Gene Ther., 2, 357-362.
13. FRENCH-ANDERSON W. (1992): The first signs of danger. Hum. Gene Ther., 3, 359-360.
14. GLORIOSO J. C., DELUCA N. A., GOINS W. F. and FINK D. (1994): In WOLFF J. A. (ed.): Gene therapeutics. Methods and applications of direct gene transfer. Birkhauser, Boston, 281-302.
15. GROSSMAN M., RADER D. J., MULLER D. W., KOLANSKY D. M., KOZARSKY K., CLARK B. J. 3rd, STEIN E. A., LUPIEN P. J., BREWER H. B. JR. and RAPER S. E. (1995): A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Med., 1, 1148-1154.
16. HIJARD J., ROY R., BOUCHARD J. P., MALOUIN F. and RICHARDS C. L. (1992): Human myoblast transplantation between immunohistocompatible donors and recipients produces immune reactions. Transplant. Proc., 24, 3049-3051.
17. HUXLEY C. (1994): Mammalian artificial chromosomes: a new tool for gene therapy. Gene Ther., 1, 7-12.
18. HUYGEN K., CONTENT J., DENIS O., MONTGOMERY D. L., YAWMAN A. M., DECK R. R., DEWITT C. M., ORME I. M., BALDWIN S., D'SOUZA C., DROWART A., LOZES E., VANDENBUSSCHE P., VAN VOOREN J. P., LIU M. A. and ULMER J. B. (1996): Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nature Med., 2, 893-898.
19. KNOWLES M. R., HOHNEKER K. W., ZHOU Z., OLSEN J. C., NOAH T. L., HU P. C. LEIGH M. W., ENGELHARDT J. F., EDWARDS L. J. and JONES K. R. (1995): A controlled study of adenoviral-vector-ediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med., 333, 823-831.
20. KOCHANEK S., CLEMENS P. R., MITANI K., CHEN H. H., CHAN S. and CASKEY C. T. (1996): A new adenoviral vector. Replacement of all viral coding sequences with 2 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA., 93, 5731-5736.
21. KREMER E. J. and PERRICAUDET M. (1995): Adenovirus and adeno-associated virus mediated gene transfer. In LEVER A. M. L. and GOODFELLOW P. (eds.): Gene therapy. Br. Med. Bull., 51, 31-44.
22. KUMAR V. and SERCARZ E. (1996): Genetic vaccination: the advantages of going naked. Nature Med., 2, 857-859.
23. KUMAR-SINGH R. and CHAMBERLAIN J. S. (1996) Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet., 5, 913-921.
24. LATCHMAN D. S. (1994): Herpes simplex: once bitten, forever smitten. In LATCHMAN D. S. (ed.): From genetics to gene therapy. Bios. Sci. Publishers Ltd., Oxford, 235-254.
25. LEDLEY F. D. (1995): Nonviral gene therapy. The promise of genes as pharmaceutical products. Hum. Gene Ther., 6, 1129-1144.
26. LEDLEY F. D. (1966): Our study is man (and woman). Hum. Gene Ther., 7, 1193-1195.
27. MARSHALL E. (1995): Gene therapy's growing pains. Science, 269, 1050-1055.
28. MCLACHLAN G., DAVIDSON D. J., STEVENSON B. J., DICKINSON P., DAVIDSON-SMITH H., DORIN J. R. and PORTEOUS D. J. (1995): Evaluation in vitro and in vivo of cationic liposome-expression construct complexes for cystic fibrosis gene therapy. Gene Ther., 2, 614-622.
29. MENDELL J. R., KISSEL J. T., AMATO A. A., KINO W., SIGNORE L., PRIOR T. W., SAHENK Z., BENSON S., MCANDREW P. E. and RICE R. (1995): Myoblast transfer in the treatment of Duchenne's muscular dystrophy N. Engl. J. Med., 333, 832-838.
30. MORGAN J. R., LEDOUX J. M., SNOW R. G., TOMPKINS R. G. and YARMUSH M. L. (1995): Retrovirus infection: effect of time and target cell number. J. Virol., 69, 6994-7000.
31. NING-SUN Y., DE LUNA C. and CHENG L. (1994): Gene transfer via particle bombardment. Application of the Accell gene gun. In WOLFF J. A. (ed.): Gene therapeutics. Methods and applications of direct gene transfer. Birkhauser, Boston, 193-209.
32. RIGG R. J., CHEN J., DANDO J. S., FORESTELL S. P., PLAVEC I. and BOHNLEIN E. (1996): A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. Virology, 218, 290-295.
33. RIVERA V. M., CLACKSON T., NATESAN S., POLLOCK R., AMARA J. F., KEENAN T., MAGARI S. R., PHILLIPS T., COURAGE N. L., CERASOLI F., HOLT D. A. and GILMAN M. (1996): A humanized system for pharmacologic control of gene expression. Nature Med., 2, 1028-1032.
34. SATO Y., ROMAN M., TIGHE H., LEE D., CORR M., NGUYEN M. D., SILVERMAN G. J., LOTZ M., CARSON D. A. and RAZ E. (1996): Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science, 273, 352-354.
35. SHAUGHNESSY E., LU D., CHATTERJEE S. and WONG K. K. (1996): Parvoviral vectors for the gene therapy of cancer. Semin. Oncol., 23, 159-171.
36. SINGHAL A. M. and HUANG I. (1994): Gene transfer in mammalian cells using liposomes as carriers. In WOLFF J. A. (ed.): Birkhauser, Boston, 118-142.
37. SMITH K. T., SHEPHERD A. J., BOYD J. E. and LEES G. M. (1996): Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. Gene Ther., 3, 190-200.
38. STRATFORD-PERRICAUDET L. D. and PERRICAUDET M. (1994): Gene therapy: the advent of adenovirus. In WOLFF J. A. (ed.): Gene therapeutics. Methods and applications of direct gene transfer. Birkhauser, Boston, 344-362.
39. TAKEUCHI Y., COSSET F., LACHMANN P. J., OKADA H., WEISS R. A. and COLLINS M. K. (1994): Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J. Virol., 68, 8001-8007.
40. TASCON R. E., COLSTON M. J., RAGNO S., STAVROPOULOS E., GREGORY D. and LOWRIE D. B. (1996): Vaccination against tuberculosis by DNA injection. Nature Med., 2, 888-892.
41. TRIPATHY S. K., BLACK H. B., GOLDWASSER E. and LEIDEN J. M. (1996): Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med., 2, 545-550.
42. VILE R. G. and HART I. R. (1994): Targeting of cytokine gene expression to malignant melanoma cells using tissue specific promoter sequences. Ann. Oncol., 4, (suppl. 5), 59-65.
43. VILE R. G. and RUSSELL S. J. (1995): Retroviruses as vectors. In LEVER A. M. L. and GOODFELLOW P. (eds.): Gene therapy. Br. Med. Bull., 51, 12-30.
44. VILQUIN J. T., WAGNER E., KINOSHITA I., ROY R. and TREMBLAY J. P. (1995): Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin. J. Cell. Biol., 131, 975-988.
45. WAISMAN A., RUIZ P. J., HIRSCHBERG D. L., GELMAN A., OKSENBERG J. R., BROCKE S., MOR F., COHEN I. R. and STEINMAN L. (1996): Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nature Med., 2, 899-905.
46. WEISS R. A. (1994): Retrovirus receptors on human cells. In LATCHMAN D. S. (ed.): From genetics to gene therapy. Bios. Sci. Publishers Ltd., Oxford, 147-160.
47. WELLS D. J. (1993): Improved gene transfer by direct plasmid injection associated with regenaration in mouse skeletal muscle. FEBS Lett., 332, 179-182.
48. WHALEN R. G. (1994): Promoters, enhancers and inducible elements for gene therapy. In WOLFF J. A. (ed.): Gene therapeutics. Methods and applications of direct gene transfer. Birkhauser, Boston, 60-79.
49. WILKINSON G. W. G., DARLEY R. L. and LOWENSTEFN P. R. (1994): Viral vectors for gene therapy. In LATCHMAN D. S. (ed.): From genetics to gene therapy. Bios Sci. Publisher Ltd., Oxford.
50. WILSON J. M. (1996): Adenoviruses as gene-delivery vehicles. N. Engl. J. Med., 334, 1185-1187.
51. YANG Y., HAECKER S. E., SU Q. and WILSON J. M. (1996): Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum. Mol. Genet., 5, 1703-1712.
52. YANG Y., LI Q., ERTL H. C. and WILSON J. M. (1995): Cellular and humoral immune response to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol., 69, 2004-2015.
53. ZHU N., LIGGITT D., LIU Y. and DEBS R. (1993): Systemic gene expression after intravenous DNA delivery into adult mice. Science, 261, 209-211.